2019冠状病毒病的潜在治疗方法；叙述性文献综述
Potential Treatments for COVID-19; a Narrative Literature Review.
作者信息
Rismanbaf Ali
机构信息
Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
出版信息
Arch Acad Emerg Med. 2020 Mar 21;8(1):e29. eCollection 2020.
Abstract
SARS-CoV-2 is a newly emerging human infectious coronavirus that causes COVID-19, which has been recognized as a pandemic by the World Health Organization (WHO) on March 11. There is still no vaccine or definitive treatment for this virus because its pathogenesis and proliferation pathways are still unknown. Therefore, in this article, new potential COVID-19 therapies are briefly reviewed.
摘要
严重急性呼吸综合征冠状病毒2（SARS-CoV-2）是一种新出现的可感染人类的冠状病毒，可导致2019冠状病毒病（COVID-19），世界卫生组织（WHO）于3月11日将其认定为大流行病。目前针对这种病毒仍没有疫苗或确切的治疗方法，因为其发病机制和增殖途径仍不清楚。因此，在本文中，将简要综述新型潜在的COVID-19治疗方法。
相似文献
1
Potential Treatments for COVID-19; a Narrative Literature Review.
Arch Acad Emerg Med. 2020 Mar 21;8(1):e29. eCollection 2020.
2
Glycyrrhizin as a Potential Treatment for the Novel Coronavirus (COVID-19).
Mini Rev Med Chem. 2021;21(16):2204-2208. doi: 10.2174/1389557521666210210160237.
3
Clinical trials and the COVID-19 pandemic.
Hell J Nucl Med. 2020 Jan-Apr;23(1):4-5. doi: 10.1967/s002449912014.
4
The Rationale for Potential Pharmacotherapy of COVID-19.
Pharmaceuticals (Basel). 2020 May 14;13(5):96. doi: 10.3390/ph13050096.
5
Next-generation treatments: Immunotherapy and advanced therapies for COVID-19.
Heliyon. 2024 Feb 19;10(5):e26423. doi: 10.1016/j.heliyon.2024.e26423. eCollection 2024 Mar 15.
6
Current approaches used in treating COVID-19 from a molecular mechanisms and immune response perspective.
Saudi Pharm J. 2020 Nov;28(11):1333-1352. doi: 10.1016/j.jsps.2020.08.024. Epub 2020 Sep 1.
7
SARS-CoV-2: Mechanism of infection and emerging technologies for future prospects.
Rev Med Virol. 2021 Mar;31(2):e2168. doi: 10.1002/rmv.2168. Epub 2020 Sep 16.
8
An evidence-based systematic review on emerging therapeutic and preventive strategies to treat novel coronavirus (SARS-CoV-2) during an outbreak scenario.
J Basic Clin Physiol Pharmacol. 2020 Sep 14;31(6):jbcpp-2020-0113. doi: 10.1515/jbcpp-2020-0113.
9
Pathogenesis-directed therapy of 2019 novel coronavirus disease.
J Med Virol. 2021 Mar;93(3):1320-1342. doi: 10.1002/jmv.26610. Epub 2020 Nov 10.
10
SARS-CoV-2: Immune Response Elicited by Infection and Development of Vaccines and Treatments.
Front Immunol. 2020 Dec 11;11:569760. doi: 10.3389/fimmu.2020.569760. eCollection 2020.
引用本文的文献
1
SARS-CoV-2 Evolution: Implications for Diagnosis, Treatment, Vaccine Effectiveness and Development.
Vaccines (Basel). 2024 Dec 28;13(1):17. doi: 10.3390/vaccines13010017.
2
Epidemiology of Injury and Illness in North American Professional Men's Soccer: Comparing COVID-19 Lockdown With Previous Seasons.
Sports Health. 2025 Mar;17(2):412-418. doi: 10.1177/19417381241253227. Epub 2024 May 18.
3
A comprehensive review on pharmacologic agents, immunotherapies and supportive therapeutics for COVID-19.
Narra J. 2022 Dec;2(3):e92. doi: 10.52225/narra.v2i3.92. Epub 2022 Dec 8.
4
Engineering Materials and Devices for the Prevention, Diagnosis, and Treatment of COVID-19 and Infectious Diseases.
Nanomaterials (Basel). 2023 Aug 30;13(17):2455. doi: 10.3390/nano13172455.
5
Impact of Inhaled Epoprostenol in Patients on COVID-19 Acute Respiratory Distress Syndrome (ARDS).
HCA Healthc J Med. 2023 Apr 28;4(2):181-185. doi: 10.36518/2689-0216.1563. eCollection 2023.
6
Cluster-based text mining for extracting drug candidates for the prevention of COVID-19 from the biomedical literature.
J Taibah Univ Med Sci. 2023 Aug;18(4):787-801. doi: 10.1016/j.jtumed.2022.12.015. Epub 2023 Jan 4.
7
WASH to control COVID-19: A rapid review.
Front Public Health. 2022 Aug 11;10:976423. doi: 10.3389/fpubh.2022.976423. eCollection 2022.
8
Estrogen hormone is an essential sex factor inhibiting inflammation and immune response in COVID-19.
Sci Rep. 2022 Jun 8;12(1):9462. doi: 10.1038/s41598-022-13585-4.
9
Set-Valued Control to COVID-19 Spread with Treatment and Limitation of Vaccination Resources.
Iran J Sci Technol Trans A Sci. 2022;46(3):829-838. doi: 10.1007/s40995-022-01295-5. Epub 2022 May 8.
10
Mental health status of students during coronavirus pandemic outbreak: A cross-sectional study.
Ann Med Surg (Lond). 2022 Jun;78:103739. doi: 10.1016/j.amsu.2022.103739. Epub 2022 May 11.
本文引用的文献
1
Virtual screening of approved clinic drugs with main protease (3CL) reveals potential inhibitory effects on SARS-CoV-2.
J Biomol Struct Dyn. 2022 Feb;40(2):685-695. doi: 10.1080/07391102.2020.1817786. Epub 2020 Sep 10.
2
Thalidomide combined with low-dose short-term glucocorticoid in the treatment of critical Coronavirus Disease 2019.
Clin Transl Med. 2020 Jun;10(2):e35. doi: 10.1002/ctm2.35. Epub 2020 Jun 4.
3
The role of interleukin-6 in monitoring severe case of coronavirus disease 2019.
EMBO Mol Med. 2020 Jul 7;12(7):e12421. doi: 10.15252/emmm.202012421. Epub 2020 Jun 5.
4
Reduction and Functional Exhaustion of T Cells in Patients With Coronavirus Disease 2019 (COVID-19).
Front Immunol. 2020 May 1;11:827. doi: 10.3389/fimmu.2020.00827. eCollection 2020.
5
Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study.
J Chem Inf Model. 2020 Jun 22;60(6):3277-3286. doi: 10.1021/acs.jcim.0c00179. Epub 2020 May 4.
6
Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model.
Comput Struct Biotechnol J. 2020 Mar 30;18:784-790. doi: 10.1016/j.csbj.2020.03.025. eCollection 2020.
7
Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL ) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates.
F1000Res. 2020 Feb 21;9:129. doi: 10.12688/f1000research.22457.2. eCollection 2020.
8
Potential inhibitors against 2019-nCoV coronavirus M protease from clinically approved medicines.
J Genet Genomics. 2020 Feb 20;47(2):119-121. doi: 10.1016/j.jgg.2020.02.001. Epub 2020 Feb 13.
9
Rapid Identification of Potential Inhibitors of SARS-CoV-2 Main Protease by Deep Docking of 1.3 Billion Compounds.
Mol Inform. 2020 Aug;39(8):e2000028. doi: 10.1002/minf.202000028. Epub 2020 Mar 23.
10
Breakthrough: Chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies.
Biosci Trends. 2020 Mar 16;14(1):72-73. doi: 10.5582/bst.2020.01047. Epub 2020 Feb 19.
Zotero 插件